Opinion

Video

Optimizing Therapy Sequencing in CLL

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Roy Beveridge, MD

A panel of experts discuss optimizing therapy sequencing in CLL.

Video content above is prompted by the following question(s):

  • How do you determine the optimal sequencing of therapies for patients with CLL?
  • How does prior therapy exposure influence your choice of subsequent treatments?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
5 experts in this video
5 experts in this video
Related Content
While improvements were seen in non-relapse mortality in CLL throughout the decade, the researchers observed no differences in overall survival or progression-free survival. | Image credit: LASZLO - stock.adobe.com
June 9th 2025

New Era of CLL Treatments Brings Changes to Use of HSCT

AJMC Contributor
With a 42% reduction seen in the use of hematopoietic stem cell transplantation (HSCT) throughout the decade, researchers suggest that transplantation may be reserved for more fit patients.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
People with CLL had significant mortality rates throughout the study years, which spanned the timeframe from the onset of the pandemic through February 2023. | Image credit: phonlamaiphoto - stock.adobe.com
May 29th 2025

CLL Linked With Worse COVID-19 Outcomes in Early Pandemic

Jared Kaltwasser
People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of the pandemic, a Swedish study found.
Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com
May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor
The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
Other AF prediction models have been proposed, including one with a machine-learning approach, but earlier models may not apply to patients taking second-generation BTKis. | Image Credit: sovova - stock.adobe.com
May 15th 2025

Novel AI-Based Score Could Pinpoint AF Risk in Patients With CLL on BTKis

Jared Kaltwasser
A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).
While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com
May 1st 2025

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

AJMC Contributor
Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo